The Baruch S. Blumberg Institute is an American non-profit research institute based in Doylestown, Pennsylvania. It is a subsidiary of the Hepatitis B Foundation.[1]
History
The institute was founded in 2003.[1:1]
Funding
The institute has received funding from:[2][3][4]
- America's Charities
- Amgen Foundation
- Arcinova
- Arthur J. Gallagher & Co
- BioAdvance
- BLA Regulatory
- Carta
- Celerion
- Frontage Laboratories
- Johnson & Johnson
- Lyophilization Technology
- Medix
- Merck Foundation
- Merrill Lynch
- Network for Good
- Poretta & Orr
- Tunnell Consulting
- United States Department of Defense
External links
About Us. Blumberg Institute. Retrieved June 26, 2023, from https://web.archive.org/web/20230626071723/https://www.blumberginstitute.org/about/our-mission/ ↩︎ ↩︎
Cohen, C. (2023). 2022 Annual Report (pp. 18–21). Hepatitis B Foundation. https://web.archive.org/web/20230314121341/https://www.hepb.org/assets/Uploads/HepB-2022-Annual-Report-v1-2.21.23.pdf ↩︎
Block, T. M. (2022, July 6). Annual Report 2021. Issuu; Hepatitis B Foundation. https://web.archive.org/web/20230626072726/https://issuu.com/hepbfoundation/docs/hepb-2021_annual_report-v8_7-6 ↩︎
Block, T. M., & Rosen, J. 2020 Annual Report. Hepatitis B Foundation. Retrieved June 26, 2023, from https://web.archive.org/web/20230626232802/https://www.hepb.org/assets/Uploads/HepB-2020-Annual-Report-FINAL2.pdf ↩︎
